Guardian Pharmacy Total Liab Over Time
GRDN Stock | 25.00 0.35 1.42% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Guardian Pharmacy Performance and Guardian Pharmacy Correlation. Guardian |
Is Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardian Pharmacy. If investors know Guardian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardian Pharmacy listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Guardian Pharmacy is measured differently than its book value, which is the value of Guardian that is recorded on the company's balance sheet. Investors also form their own opinion of Guardian Pharmacy's value that differs from its market value or its book value, called intrinsic value, which is Guardian Pharmacy's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardian Pharmacy's market value can be influenced by many factors that don't directly affect Guardian Pharmacy's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardian Pharmacy's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardian Pharmacy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardian Pharmacy's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Liab Analysis
Compare Guardian Pharmacy and related stocks such as SNDL Inc, Axalta Coating Systems, and Chester Mining Total Liab Over Time
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SNDL | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 12 M | 118.1 M | 288.8 M | 25.2 M | 98.1 M | 231.7 M | 243.8 M | 140.1 M |
AXTA | 1.2 B | 1.2 B | 1.2 B | 5.5 B | 5.1 B | 4.7 B | 4.6 B | 5.4 B | 5.4 B | 5.4 B | 5.7 B | 5.7 B | 5.6 B | 5.5 B | 5.5 B |
Guardian Pharmacy and related stocks such as SNDL Inc, Axalta Coating Systems, and Chester Mining Total Liab description
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.My Equities
My Current Equities and Potential Positions
Guardian Pharmacy Services, | GRDN |
Specialization | Healthcare, Medical Care Facilities |
Location | Georgia; U.S.A |
Exchange | New York Stock Exchange |
null 25.0
Check out Guardian Pharmacy Performance and Guardian Pharmacy Correlation. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Guardian Pharmacy technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.